Breaking News Instant updates and real-time market news.

WBA

Walgreens Boots Alliance

$75.55

0.83 (1.11%)

, AMZN

Amazon.com

$1,811.22

50.23 (2.85%)

14:23
10/16/18
10/16
14:23
10/16/18
14:23

Walgreens CEO says buyout of AmerisourceBergen possible, Bloomberg reports

Walgreens Boots Alliance (WBA) CEO Stefano Pessina believes it will be easier for his company to move online than it will be for Amazon (AMZN) to build out a brick-and-mortar physical store footprint, reported Bloomberg, citing an interview with the executive. Speaking about Amazon, Pessina said, "I don't believe it is a big threat. It will be another competitor, but I don't think we'll disappear because of Amazon. We'll adapt." Discussing CVS Health's (CVS) planned acquisition of Aetna (AET), Pessina is quoted as having said: "We should have bought an insurance company four years ago when our multiple was higher than their multiple. At the time, we were engaged with Rite Aid (RAD)." Walgreens currently owns 26% of drug distributor AmerisourceBergen (ABC) and Pessina didn't rule out the possibility, which has previously been raised by The Wall Street Journal, of a buyout. He told Bloomberg, "It is something that could happen at a certain point, maybe yes, maybe no." He added there was no rush to do so, because "we control them strategically," and said any deal would have to be made at the right price, Bloomberg said. Reference Link

WBA

Walgreens Boots Alliance

$75.55

0.83 (1.11%)

AMZN

Amazon.com

$1,811.22

50.23 (2.85%)

CVS

CVS Health

$73.05

0.01 (0.01%)

AET

Aetna

$199.90

0.88 (0.44%)

ABC

AmerisourceBergen

$92.51

2.93 (3.27%)

RAD

Rite Aid

$1.05

-0.005 (-0.48%)

  • 16

    Oct

  • 16

    Oct

  • 17

    Oct

  • 25

    Oct

  • 06

    Nov

WBA Walgreens Boots Alliance
$75.55

0.83 (1.11%)

10/12/18
RHCO
10/12/18
NO CHANGE
Target $75
RHCO
Hold
Walgreens Boots Alliance price target raised to $75 from $66 at SunTrust
SunTrust analyst David MacDonald raised his price target on Walgreens Boots Alliance (WBA) to $75 after its Q4 earnings beat and FY19 guidance yesterday. The analyst says the results were marked by "solid U.S. pharmacy performance" in spite of the ongoing reimbursement and generic headwinds. MacDonald also keeps his Hold rating, adding that while the company's cash flow remains "robust" and the integration of Rite Aid (RAD) is still on track, he is concerned about the challenging environment and ongoing degradation in gross margins.
10/12/18
LOOP
10/12/18
NO CHANGE
Target $82
LOOP
Buy
Walgreens Boots Alliance price target raised to $82 at Loop Capital
Loop Capital analyst Andrew Wolf raised his price target on Walgreens Boots Alliance to $82 from $80 after its Q4 earnings beat and "constructive" outlook for FY19. The analyst notes however that earnings quality was "mixed", with upside coming from lower-than-modeled share count and tax rate along with curtailment of some of the employee benefits. Wolf also keeps his Buy, noting that the management's FY19 guidance was set "conservatively" with some optimism of normalizing gross margins.
10/08/18
RBCM
10/08/18
NO CHANGE
Target $82
RBCM
Outperform
Walgreens Boots Alliance price target raised to $82 from $68 at RBC Capital
RBC Capital analyst George Hill raised his price target on Walgreens Boots Alliance to $82 and kept his Outperform rating ahead of its Q4 results and FY19 guidance this week, saying its outlook should come in better than expected thanks to the company's share repurchases. The analyst warns that he still has some concerns about Walgreens Boots' pricing in the U.S. after its commentary that followed the Q3 results but still expects the Medicare Part D preferred pharmacy network business to recover next year from the headwinds experienced in 2018. Hill also expects investors to focus on the company's organic script growth expectation as well as its "partnership strategy, pharmacy reimbursement trends, and drug pricing or regulatory changes".
10/03/18
WELS
10/03/18
NO CHANGE
WELS
Outperform
Pharmacy business sale could be next step for Kroger, says Wells Fargo
Wells Fargo analyst Edward Kelly believes Kroger (KR) has taken aggressive steps recently to better position itself for the long-term, and a potential next step could be the sale of its pharmacy business. The analyst notes that the strategic argument is stronger than ever given structural changes in pharmacy, an underappreciated opportunity to unlock material value, and it seems highly aligned with management's more progressive approach. Recent news of a partnership with Walgreens Boots Alliance (WBA) on a store pilot should not be overlooked, he adds, as dialogue between the companies on ways to create value could foretell a more significant relationship. Kelly reiterates an Outperform rating on Kroger shares.
AMZN Amazon.com
$1,811.22

50.23 (2.85%)

10/16/18
LOOP
10/16/18
NO CHANGE
Target $107
LOOP
Buy
Reported Icahn stake in Dollar Tree a positive development, says Loop Capital
Loop Capital analyst Anthony Chukumba views the New York Post's report of Carl Icahn taking a "significant" stake in Dollar Tree (DLTR) as "unsurprising" and a "positive development." Icahn previously acquired a stake in Family Dollar, pressured management to seek a buyer, and reportedly made a $200M profit on his investment when the company was acquired by Dollar Tree in 2015 for $8.5B, Chukumba tells investors in a research note. The analyst believes it was just a matter of time before an activist became involved given the Family Dollar segment's continued struggles while the core Dollar Tree segment "remains one of the best performers in deep discount retailing." He thinks Icahn is likely to pressure Dollar Tree management to quickly improve the performance of Family Dollar significantly or sell the division. There would be several interested parties if Dollar Tree put Family Dollar on the block, including Dollar General (DG), Amazon.com (AMZN) and private equity firms, Chukumba predicts. He reiterates a Buy rating on Dollar Tree shares with a $107 price target. The stock in afternoon trading is up 6.5%, or $5.23, to $86.20 following the New York Post's report.
10/16/18
DADA
10/16/18
NO CHANGE
Target $60
DADA
Underperform
Path to Wayfair margin target taking longer, says DA Davidson
DA Davidson analyst Tom Forte kept his Underperform rating and $60 price target on Wayfair (W), also maintaining his estimated long-term EBITDA margin level of 8% - the low end of 8%-10% company target range. The analyst notes that the path to that margin will take longer to achieve than implied in the current stock price. Forte also states that Wayfair will have to sustain investments at a high level relative to revenues to preserve its "impressive" sales growth rate. Forte further notes that although Wayfair is modeling Amazon's (AMZN) shipping membership program with its MyWay initiative, its lack of the Market Place and cloud computing leave him with little confidence that it can generate greater profitability any sooner.
10/15/18
MSCO
10/15/18
NO CHANGE
Target $2500
MSCO
Overweight
Amazon wage hike impact 'not small,' but manageable, says Morgan Stanley
Morgan Stanley analyst Brian Nowak said Amazon's wage increases are "not small," estimating that the pay hikes for U.S. and UK employees will increase operating expenses by about $2.75B, or about 2.5%, in FY19. However, he believes the cost will be manageable as he Nowak believes the company's warehouse build over the past 2-3 years had a larger robotics integration, which is driving increased fulfillment efficiency. He keeps an Overweight rating and $2,500 price target on Amazon shares.
10/16/18
SBSH
10/16/18
NO CHANGE
SBSH
Buy
Increased Postal Service rates could cost Amazon $1B, says Citi
Last week the United States Postal Service unveiled a proposed plan for increases in mailing rates to be effective January 2019, Citi analyst Mark May tells investors in a research note. The analyst estimates that Amazon's U.S. shipping costs could increase by $1B in 2019 as a result of the USPS proposal. Without any offsets, this equates to 0.8% of May's 2019 gross profit estimate and 5.7% of his operating profit forecast. That said, he believes Amazon has "several levers" to offset this potential impact, including the $20 per year increase in U.S. Prime subscription fees and increasing its shipping fees charged to third-party sellers. May keeps a Buy rating on Amazon shares.
CVS CVS Health
$73.05

0.01 (0.01%)

08/27/18
RBCM
08/27/18
NO CHANGE
Target $94
RBCM
Outperform
Express Scripts price target raised to $94 from $90 at RBC Capital
RBC Capital analyst George Hills raised his price target on Express Scripts (ESRX) to $94 and kept his Outperform rating, citing the shareholders' "blessing" of the merger with Cigna (CI). The analyst notes that even though the regulators are yet to rule on the deal, he expects the merger to close by the end of the year and has a positive view of the "vertical consolidation thesis" for the company. Hill adds that the chance of a Department of Justice challenge to the merger is small in light of the seemingly clear path of the CVS (CVS) - Aetna (AET) merger, but if regulators do seek concessions, he expects the necessary divestitures to be small.
09/20/18
LEER
09/20/18
NO CHANGE
Target $250
LEER
Outperform
Cigna price target raised to $250 from $235 at Leerink
Leerink analyst Ana Gupte raised her price target on Outperform-rated Cigna (CI) to $250 from $235 following meetings with a panel of PBM and Specialty Rx specialists, which increased her bullishness on Cigna and Market Perform-rated Express Scripts (ESRX). In a research note to investors, Gupte says she also came away with raised confidence on the achiveability of the $4B annual drug cost savings from the Express Scripts switch by Anthem (ANTM) to IngenioRx in partnership with CVS (CVS). She adds that smaller independent PBMs still have niche opportunities with smaller regional third-party health plans, noting that Magellan Health (MGLN) is well positioned in this market, though loss of substantial business in Florida Seriously Mentally Ill is a headwind in Rx as well.
09/17/18
RBCM
09/17/18
NO CHANGE
Target $101
RBCM
Outperform
CVS Health price target raised to $101 from $90 at RBC Capital
RBC Capital analyst George Hill raised his price target on CVS Health (CVS) to $101 and kept his Outperform rating, citing the increased visibility of the company's merger with Aetna (AET) after its recent comments that it expects the deal to close in early Q4. The analyst also points to "de-risked" CVS investment thesis as it pertains to pharmacy benefit managers rebates and the much higher relative multiples for managed care companies, even though he warns that investors may still be spooked by any potential steps that the White House takes to drive prescription drug prices lower. Hill notes however that the latest government funding bill pulled the text that required drug companies to disclose prices in their ads, implying that the political will to change status quo may be limited.
08/23/18
08/23/18
NO CHANGE

Fly Intel: Today's top analyst calls on Wall Street
Check out today's top analyst calls from around Wall Street, compiled by The Fly. ROSENBLATT BOOSTS AMD PRICE TARGET TO STREET HIGH: Rosenblatt analyst Hans Mosesmann raised his price target for AMD (AMD) shares to $30 from $27. Mosesmann's new price target represents the high among Wall Street sell-side analysts. Following the meetings, Mosesmann has renewed conviction in AMD's multi-year double digit growth profile. Further, he's impressed by the analysis investors are doing in the name after years of disregard. AMD is up 4.1% in late morning trading. CANTOR CUTS AETNA TO NEUTRAL: Cantor Fitzgerald analyst Steven Halper downgraded Aetna (AET) to Neutral from Overweight with a price target of $202. The stock now trades at just a 4.6% discount to the implied CVS Health (CVS) acquisition value of about $207 per share, Halper said. He believes the narrowed deal spread reflects an increased likelihood of regulatory approval. Halper cites limited potential upside for his downgrade of Aetna to Neutral. NIELSEN UPGRADED TO NEUTRAL AT GOLDMAN: Goldman Sachs analyst George Tong upgraded Nielsen Holdings (NLSN) to Neutral and raised his price target for the shares to $25 from $20. With activist Elliott Management pushing for a sale and increased deal activity in the Information Services sector, Tong sees increased likelihood of Nielsen being involved in a transaction. His upgrade to Neutral and price target increase come after the analyst incorporated a potential takeover into his model. Nielsen is up 3.3% in late morning trading. IMPERIAL SEES SUBSCRIBER UPSIDE FOR NETFLIX: Imperial Capital analyst David Miller believes Netflix's (NFLX) experiment with ending billing through Apple's (AAPL) app store in 33 countries outside the U.S. likely implies upside to its Q3 international subscriber guidance. The analyst said he has a tough time believing that Netflix would "experiment" with billing infrastructure mid-quarter if it did not believe that its international subscriber levels were trending ahead of guidance. As such, Miller raised his Q3 international subscriber estimate to 4.46M from 4.35M. He kept an Outperform rating on Netflix with a $494 price target. TARGET GETS UPGRADE AND DOWNGRADE: Target (TGT) was upgraded to Outperform from Market Perform at Telsey Advisory, and downgraded to Peer Perform from Outperform at Wolfe Research.
AET Aetna
$199.90

0.88 (0.44%)

09/10/18
SDLR
09/10/18
INITIATION
Target $60
SDLR
Buy
Hartford Financial initiated with a Buy at Sandler ONeill
Sandler ONeill analyst Paul Newsome initiated Hartford Financial (HIG) with a Buy rating and $60 price target, citing his view that its valuation is "relatively attractive" and that the biggest near-term risk for investors has been resolved by the purchase of The Navigators Group (NAVG), which he sees having several benefits. Newsome also believes the recent acquisition of Aetna's (AET) benefits business will be a relatively strong earnings growth opportunity, he tells investors.
10/02/18
LEER
10/02/18
NO CHANGE
LEER
Outperform
Intersect ENT's Sinuva reimbursement policies 'steps in right direction,' says Leerink
Leerink analyst Richard Newitter reiterates an Outperform rating on Intersect ENT following some positive progress on the reimbursement front for Sinuva in the last several weeks, namely Aetna (AET) covering Sinuva and Anthem (ATNM) adding it to its formulary this past week. The analyst believes these positive coverage policies represent steps in the right direction to a potentially quicker and more consistent reimbursement process using the specialty pharmacy channel, an area where the company has faced some challenges.
ABC AmerisourceBergen
$92.51

2.93 (3.27%)

07/20/18
07/20/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Philip Morris (PM) downgraded to Neutral from Overweight at JPMorgan and to Market Perform from Outperform at Cowen. 2. Skechers (SKX) downgraded to Neutral from Positive at Susquehanna and to Market Perform from Outperform at Wells Fargo. 3. McKesson (MCK), AmerisourceBergen (ABC), and Express Scripts (ESRX) downgraded to Neutral from Outperform at Baird. 4. Five Below (FIVE) downgraded to Neutral from Outperform at Credit Suisse with analyst Judah Frommer saying he is moving to the sidelines as he sees risk/reward balanced at current levels given the stock's material outperformance and back-half comp acceleration that he believes is priced into shares. 5. Yum China (YUMC) downgraded to Underperform from Neutral at BofA/Merrill with analyst Chen Luo saying he expects Yum China to continue to underperform given a likely peak in KFC trends amid China's weakening macro environment, a likely prolonged turnaround at Pizza Hut combined with heavy costs, a slowdown in Chinese consumer consumption, and RMB depreciation. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
07/20/18
BARD
07/20/18
DOWNGRADE
BARD
Neutral
Express Scripts, AmerisourceBergen, McKesson cut to Neutral at Baird
As previously reported, Baird analyst Eric Coldwell downgraded Express Scripts (ESRX), AmerisourceBergen (ABC) and McKesson (MCK), all to Neutral from Outperform, citing the heavy political attack in recent weeks against PBMs and members of the drug supply chain. Among them, he said AmerisourceBergen remains his preferred name, but he cannot justify putting new money to work in these names in the current environment, stating that visibility has deteriorated further across the supply chain.
07/20/18
BARD
07/20/18
DOWNGRADE
BARD
Neutral
AmerisourceBergen downgraded to Neutral from Outperform at Baird
07/20/18
07/20/18
NO CHANGE

Fly Intel: Today's top analyst calls on Wall Street
Check out today's top analyst calls from around Wall Street, compiled by The Fly. BOFA CUTS YUM CHINA TO UNDERPERFORM: BofA Merrill Lynch analyst Chen Luo downgraded Yum China (YUMC) to Underperform from Neutral and cut its price target to $34 from $44.30. Luo said he expects Yum China to continue to underperform given a likely peak in KFC trends amid China's weakening macro environment, a likely prolonged turnaround at Pizza Hut combined with heavy costs, a slowdown in Chinese consumer consumption, and RMB depreciation. Yum China is down 4.8% in late morning trading. CREDIT SUISSE CUTS FIVE BELOW TO NEUTRAL: Credit Suisse analyst Judah Frommer downgraded Five Below (FIVE) to Neutral from Outperform, telling investors that he is moving to the sidelines as he sees risk/reward balanced at current levels given the stock's material outperformance and back-half comp acceleration that he believes is priced into shares. Frommer keeps his $110 price target and says Five Below remains one of the most differentiated concepts in retail. Five Below is down 4.4% in late morning trading. BAIRD MORE CAUTIOUS ON DRUG SUPPLY CHAIN: Baird analyst Eric Coldwell downgraded Express Scripts (ESRX), AmerisourceBergen (ABC), and McKesson (MCK), all to Neutral from Outperform, citing the heavy political attack in recent weeks against pharmacy benefit managers and members of the drug supply chain. Among them, he said AmerisourceBergen remains his preferred name, but he cannot justify putting new money to work in these names in the current environment. SUNTRUST STARTS VIKING WITH A BUY: SunTrust analyst Edward Nash initiated Viking Therapeutics (VKTX) with a Buy rating and a price target of $14, saying its VK2809 drug for lipid disorders "has the potential to become a promising treatment by addressing multiple metabolic issues" associated with the non-alcoholic steatohepatitis disease, or NASH. Viking is up 8.3% in late morning trading. JPMORGAN SAYS BUY GM, SELL TESLA INTO EARNINGS: JPMorgan analyst Ryan Brinkman forecast lower than consensus Q2 earnings for Ford (F) and higher than consensus earnings for General Motors (GM). The analyst is also concerned about the potential for a "large loss and accompanying large cash outflow" at Tesla (TSLA) in Q2 to "make the bridge" to GAAP profitability and positive cash generation in the second half of the year. Brinkman maintained Overweight ratings on GM and Ford, with a preference for GM shares. He also kept his cautious Underweight rating on Tesla shares, seeing 44% downside to his $180 December 2018 price target.
RAD Rite Aid
$1.05

-0.005 (-0.48%)

09/10/18
LOOP
09/10/18
NO CHANGE
Target $2
LOOP
Hold
Fred's sells pharmacy files to Walgreens for 'good valuation,' says Loop Capital
Loop Capital analyst Andrew Wolf noted that Fred's (FRED) announced that Walgreens (WBA) will acquire pharmacy prescription files and related pharmacy inventory of 185 Fred's stores located across 10 Southeastern states subject to regulatory approval. The deal values the prescript files at $165M, which the analyst views as a "good valuation" particularly since Walgreens will also acquire the associated pharmacy inventory for up to $36M. Wolf believes the strategic basis for Walgreens to pay this "solid" valuation for the prescription files from Fred's was fortified by its recent purchase of 1,932 Rite Aid (RAD) stores, many in the same Southeastern footprint as Fred's. The analyst reiterates a Hold rating and $2 price target on Fred's shares.
09/28/18
LOOP
09/28/18
NO CHANGE
Target $1.35
LOOP
Hold
Rite Aid price target lowered to $1.35 at Loop Capital on Albertsons deal
Loop Capital analyst Andrew Wolf lowered his price target on Rite Aid to $1.35 from $1.75 and kept his Hold rating after its Q2 results, saying that while the Pharmacy Services segment showed improved sales profitability, this was offset by lower profitability in Retail Pharmacy. The analyst added that the discount on the Rite Aid stock relative to the broader pharmacy group is "appropriate" given its "high debt leverage and subscale operations". Wolf further notes that the board's caving to shareholder pressure to cancel the Albertsons deal was a mistake directly linked to the 28% decline in the stock price since August 8th.
09/06/18
09/06/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Rite Aid (RAD) reinstated with a Sell at Goldman Sachs. 2. Parker-Hannifin (PH) initiated with an Overweight at Barclays. 3. iRhythm (IRTC) initiated with a Buy at Chardan. 4. Sarepta (SRPT) initiated with an Outperform at Credit Suisse. 5. Xperi (XPER) initiated with a Buy at National Securities. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.

TODAY'S FREE FLY STORIES

EPZM

Epizyme

$7.27

-0.31 (-4.09%)

07:46
11/15/18
11/15
07:46
11/15/18
07:46
Conference/Events
Epizyme to host conference call »

Conference call to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Dec

CZR

Caesars

$8.16

0.02 (0.25%)

07:45
11/15/18
11/15
07:45
11/15/18
07:45
Initiation
Caesars initiated  »

Caesars initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

TSE

Trinseo

$46.28

1.3 (2.89%)

07:44
11/15/18
11/15
07:44
11/15/18
07:44
Upgrade
Trinseo rating change  »

Citi upgrades Trinseo to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MGM

MGM Resorts

$25.94

0.2 (0.78%)

07:43
11/15/18
11/15
07:43
11/15/18
07:43
Initiation
MGM Resorts initiated  »

MGM Resorts initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

  • 15

    Nov

  • 19

    Nov

MBRX

Moleculin Biotech

$1.29

-0.04 (-3.01%)

07:43
11/15/18
11/15
07:43
11/15/18
07:43
Hot Stocks
Moleculin Biotech files request with FDA for pre-IND meeting for WP1732 »

Moleculin Biotech…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LVS

Las Vegas Sands

$52.45

0.9 (1.75%)

07:42
11/15/18
11/15
07:42
11/15/18
07:42
Initiation
Las Vegas Sands initiated  »

Las Vegas Sands initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

APRN

Blue Apron

$1.17

-0.055 (-4.51%)

07:41
11/15/18
11/15
07:41
11/15/18
07:41
Recommendations
Blue Apron analyst commentary  »

Blue Apron price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

JCP

J.C. Penney

$1.23

-0.05 (-3.91%)

07:40
11/15/18
11/15
07:40
11/15/18
07:40
Hot Stocks
J.C. Penney sees FY18 comparable store sales down low-single digits »

Comparable store sales…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

KBH

KB Home

$20.80

-0.135 (-0.64%)

07:39
11/15/18
11/15
07:39
11/15/18
07:39
Recommendations
KB Home analyst commentary  »

KB Home price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PANW

Palo Alto Networks

$176.83

-0.11 (-0.06%)

07:39
11/15/18
11/15
07:39
11/15/18
07:39
Recommendations
Palo Alto Networks analyst commentary  »

Palo Alto Networks…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

  • 19

    Nov

  • 29

    Nov

  • 10

    Dec

  • 09

    Jan

  • 10

    Jan

JCP

J.C. Penney

$1.23

-0.05 (-3.91%)

07:39
11/15/18
11/15
07:39
11/15/18
07:39
Earnings
J.C. Penney withdraws FY18 earnings guidance »

Given the company has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

KBH

KB Home

$20.80

-0.135 (-0.64%)

07:39
11/15/18
11/15
07:39
11/15/18
07:39
Recommendations
KB Home analyst commentary  »

KB Home price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WYNN

Wynn Resorts

$103.24

1.19 (1.17%)

07:37
11/15/18
11/15
07:37
11/15/18
07:37
Initiation
Wynn Resorts initiated  »

Wynn Resorts initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

DDS

Dillard's

$73.63

-2.74 (-3.59%)

07:37
11/15/18
11/15
07:37
11/15/18
07:37
Hot Stocks
Dillard's reports Q3 comparable store sales up 3% »

Total merchandise sales…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JCP

J.C. Penney

$1.23

-0.05 (-3.91%)

07:36
11/15/18
11/15
07:36
11/15/18
07:36
Hot Stocks
J.C. Penney CEO Jill Soltau says path to profitable growth is clear »

Jill Soltau, CEO said,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

DDS

Dillard's

$73.63

-2.74 (-3.59%)

07:36
11/15/18
11/15
07:36
11/15/18
07:36
Earnings
Dillard's reports Q3 EPS 27c, consensus 56c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

COG

Cabot Oil & Gas

$25.83

-0.67 (-2.53%)

, PAGS

PagSeguro Digital

$23.19

0.565 (2.50%)

07:36
11/15/18
11/15
07:36
11/15/18
07:36
Options
Unusual call flow in option market yesterday »

Notable call activity was…

COG

Cabot Oil & Gas

$25.83

-0.67 (-2.53%)

PAGS

PagSeguro Digital

$23.19

0.565 (2.50%)

MOS

Mosaic

$35.72

-0.41 (-1.13%)

CRC

California Resources

$24.06

0.3 (1.26%)

CVE

Cenovus Energy

$8.14

-0.205 (-2.46%)

ON

ON Semiconductor

$17.47

0.12 (0.69%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

  • 26

    Nov

  • 08

    May

JCP

J.C. Penney

$1.23

-0.05 (-3.91%)

07:34
11/15/18
11/15
07:34
11/15/18
07:34
Hot Stocks
Breaking Hot Stocks news story on J.C. Penney »

J.C. Penney reports Q3…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

CAT

Caterpillar

$125.04

-1 (-0.79%)

07:33
11/15/18
11/15
07:33
11/15/18
07:33
Recommendations
Caterpillar analyst commentary  »

Caterpillar public sector…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PAR

PAR Technology

$16.11

-0.51 (-3.07%)

07:33
11/15/18
11/15
07:33
11/15/18
07:33
Hot Stocks
PAR Technology subsidiary awarded $7.3M U.S. Navy contract at Aguada, PR »

PAR Technology announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OVID

Ovid Therapeutics

$4.75

-0.42 (-8.12%)

07:33
11/15/18
11/15
07:33
11/15/18
07:33
Initiation
Ovid Therapeutics initiated  »

Ovid Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

SPH

Suburban Propane

$22.68

0.12 (0.53%)

07:33
11/15/18
11/15
07:33
11/15/18
07:33
Earnings
Suburban Propane reports Q4 EPS (83c) vs. (83c) last year »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

OTIC

Otonomy

$2.34

-0.07 (-2.90%)

07:33
11/15/18
11/15
07:33
11/15/18
07:33
Initiation
Otonomy initiated  »

Otonomy initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

07:32
11/15/18
11/15
07:32
11/15/18
07:32
General news
U.S. stocks pointed to higher open despite UK's Brexit chaos »

U.S. futures are higher…

DNLI

Denali Therapeutics

$17.53

0.24 (1.39%)

07:32
11/15/18
11/15
07:32
11/15/18
07:32
Initiation
Denali Therapeutics initiated  »

Denali Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.